These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 17017470

  • 21. Recordkeeping and reporting requirements for drug products containing gamma-hydroxybutyric acid (GHB). Final rule.
    Drug Enforcement Administration (DEA), Justice.
    Fed Regist; 2005 Jan 04; 70(2):291-4. PubMed ID: 15630794
    [Abstract] [Full Text] [Related]

  • 22. Revision of Import and Export Requirements for Controlled Substances, Listed Chemicals, and Tableting and Encapsulating Machines, Including Changes To Implement the International Trade Data System (ITDS); Revision of Reporting Requirements for Domestic Transactions in Listed Chemicals and Tableting and Encapsulating Machines; and Technical Amendments. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2016 Dec 30; 81(251):96992-7044. PubMed ID: 28068052
    [Abstract] [Full Text] [Related]

  • 23. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2009 Apr 06; 74(64):15595-625. PubMed ID: 19507319
    [Abstract] [Full Text] [Related]

  • 24. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2005 Nov 23; 70(225):70720-30. PubMed ID: 16304736
    [Abstract] [Full Text] [Related]

  • 25. Impact of US and Canadian precursor regulation on methamphetamine purity in the United States.
    Cunningham JK, Liu LM, Callaghan R.
    Addiction; 2009 Mar 23; 104(3):441-53. PubMed ID: 19207353
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
    Food and Drug Administration, HHS.
    Fed Regist; 2006 Jun 14; 71(114):34249-51. PubMed ID: 16795943
    [Abstract] [Full Text] [Related]

  • 28. Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions.
    Callaghan RC, Cunningham JK, Victor JC, Liu LM.
    Drug Alcohol Depend; 2009 Dec 01; 105(3):185-93. PubMed ID: 19699042
    [Abstract] [Full Text] [Related]

  • 29. Controlled substances and List I chemical registration and reregistration fees. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2012 Mar 15; 77(51):15234-50. PubMed ID: 22420065
    [Abstract] [Full Text] [Related]

  • 30. Schedules of controlled substances; table of excluded nonnarcotic products: nasal decongestant inhalers manufactured by Classic Pharmaceuticals, LLC. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2010 Mar 23; 75(55):13678-9. PubMed ID: 20383920
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Exemption from import/export requirements for personal medical use. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice.
    Fed Regist; 2004 Sep 14; 69(177):55343-7. PubMed ID: 15366181
    [Abstract] [Full Text] [Related]

  • 33. Authorized sources of narcotic raw materials. Final rule.
    Fed Regist; 2008 Feb 06; 73(25):6843-51. PubMed ID: 18389916
    [Abstract] [Full Text] [Related]

  • 34. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule.
    Fed Regist; 2000 Apr 24; 65(79):21645-7. PubMed ID: 11010670
    [Abstract] [Full Text] [Related]

  • 35. Medicaid program; time limitation on price recalculations and recordkeeping requirements under the drug rebate program. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS.
    Fed Regist; 2003 Aug 29; 68(168):51912-7. PubMed ID: 12962118
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Are methamphetamine precursor control laws effective tools to fight the methamphetamine epidemic?
    Nonnemaker J, Engelen M, Shive D.
    Health Econ; 2011 May 29; 20(5):519-31. PubMed ID: 21433216
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Schedules of Controlled Substances: Table of Excluded Nonnarcotic Products: Nasal Decongestant Inhaler/Vapor Inhaler. Final rule.
    Drug Enforcement Administration, Department of Justice.
    Fed Regist; 2016 Feb 08; 81(25):6453-4. PubMed ID: 26859907
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.